Research programme Cancer Immunotherapy
Photo: Mikael Wallerstedt
The cancer immunotherapy programme at IGP comprises nine research groups that employ complementary approaches to study the role of the immune system in cancer. We also apply various methods to induce an immune attack on cancer cells. The research within the programme is both preclinical and clinical in nature, with preclinical developments being translated into early phase clinical trials.
New immunotherapy approaches
There is a strong focus on developing and verifying novel immunotherapy approaches as well as understanding mechanisms behind resistance to immunotherapy. Pathological examinations focus on understanding the immune landscape and the role of different immune cells in various forms of cancer. The clinical research includes both First-in-Human clinical trials with immunotherapies developed at IGP, and larger multi-center clinical trials.
The research groups within the programme work closely together and have at the same time a broad and international network of collaborators.
Research groups
- Rose-Marie Amini – Haematopathology
- Gunilla Enblad – Tumour biology and clinical studies of lymphomas and prostate cancer
- Magnus Essand – Cancer immunotherapy
- Mats Hellström – Markers and mechanisms in lymphoma immunotherapyMarkörer och mekanismer vid immunterapi av lymfom
- Olle Korsgren – Diabetes research
- Angelica Loskog – Immunostimulatory gene therapy for cancer
- Yumeng Mao – Dissecting the negative immune regulatory network to improve cancer immunotherapy
- Patrick Micke and Carina Strell – From tissue biology to novel diagnostic and therapeutic targets
- Gustav Ullenhag – Translational immunotherapy